CY1121783T1 - Συζευγμα αντισωματος-igf-1r-φαρμακου και η χρηση αυτου για την αγωγη του καρκινου - Google Patents

Συζευγμα αντισωματος-igf-1r-φαρμακου και η χρηση αυτου για την αγωγη του καρκινου

Info

Publication number
CY1121783T1
CY1121783T1 CY20191100523T CY191100523T CY1121783T1 CY 1121783 T1 CY1121783 T1 CY 1121783T1 CY 20191100523 T CY20191100523 T CY 20191100523T CY 191100523 T CY191100523 T CY 191100523T CY 1121783 T1 CY1121783 T1 CY 1121783T1
Authority
CY
Cyprus
Prior art keywords
antibody
drug conjugate
treatment
igf
cancer
Prior art date
Application number
CY20191100523T
Other languages
English (en)
Inventor
Ian RILATT
Michel Perez
Liliane Goetsch
Matthieu BROUSSAS
Charlotte Beau-Larvor
Jean-François HAEUW
Thierry Champion
Alain Robert
Original Assignee
Pierre Fabre Médicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pierre Fabre Médicament filed Critical Pierre Fabre Médicament
Publication of CY1121783T1 publication Critical patent/CY1121783T1/el

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Η παρούσα εφεύρεση σχετίζεται με ένα σύζευγμα αντισώματος-φαρμάκου δυνάμενο δέσμευσης IGF-1R. Από μια άποψη του θέματος, η εφεύρεση σχετίζεται με ένα σύζευγμα αντισώματος-φαρμάκου περιλαμβάνοντας ένα αντίσωμα δυνάμενο δέσμευσης σε IGF-1R, με το εν λόγω αντίσωμα να συζεύγεται σε τουλάχιστον ένα φάρμακο που επιλέγεται από παράγωγα δολαστατίνης 10 και αουριστατινών. Η εφεύρεση περιλαμβάνει επίσης μέθοδο αγωγής και τη χρήση του εν λόγω συζεύγματος αντισώματος-φαρμάκου για την αγωγή του καρκίνου.
CY20191100523T 2014-04-25 2019-05-15 Συζευγμα αντισωματος-igf-1r-φαρμακου και η χρηση αυτου για την αγωγη του καρκινου CY1121783T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14305620 2014-04-25
PCT/EP2015/059045 WO2015162291A1 (en) 2014-04-25 2015-04-27 Igf-1r antibody-drug-conjugate and its use for the treatment of cancer

Publications (1)

Publication Number Publication Date
CY1121783T1 true CY1121783T1 (el) 2020-07-31

Family

ID=50630736

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20191100523T CY1121783T1 (el) 2014-04-25 2019-05-15 Συζευγμα αντισωματος-igf-1r-φαρμακου και η χρηση αυτου για την αγωγη του καρκινου

Country Status (27)

Country Link
US (2) US10633448B2 (el)
EP (2) EP3134124B1 (el)
JP (1) JP6258523B2 (el)
KR (1) KR101795984B1 (el)
CN (1) CN106456800B (el)
AU (1) AU2015250759B2 (el)
BR (1) BR112016024619A2 (el)
CA (1) CA2946469C (el)
CY (1) CY1121783T1 (el)
DK (1) DK3134124T3 (el)
ES (1) ES2727103T3 (el)
HR (1) HRP20190888T8 (el)
HU (1) HUE044862T2 (el)
IL (1) IL248455B (el)
LT (1) LT3134124T (el)
MA (2) MA47811A (el)
MX (1) MX2016013704A (el)
MY (1) MY186711A (el)
PL (1) PL3134124T3 (el)
PT (1) PT3134124T (el)
RS (1) RS58742B1 (el)
RU (1) RU2692563C2 (el)
SA (1) SA516380120B1 (el)
SI (1) SI3134124T1 (el)
TN (1) TN2016000472A1 (el)
UA (1) UA120364C2 (el)
WO (1) WO2015162291A1 (el)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3134124T3 (da) * 2014-04-25 2019-05-06 Pf Medicament Igf-1r-antistof-lægemiddel-konjugat og dens anvendelse til behandling af kræft
JP6968790B2 (ja) 2015-10-26 2021-11-17 ピエール、ファーブル、メディカマン Igf−1r発現癌の処置のための組成物
US11340233B2 (en) 2016-03-07 2022-05-24 Pierre Fabre Medicament Universal method to capture and analyze ADCs for characterization of drug distribution and the drug-to-antibody ratio in biological samples
MX2021003295A (es) 2018-09-27 2021-07-16 Pf Medicament Enlazadores basados en sulfomaleimida y sus correspondientes conjugados.
CN111327570B (zh) 2018-12-14 2021-09-17 北京京东尚科信息技术有限公司 验证方法、装置和计算机可读存储介质
EP3735991A1 (fr) * 2019-05-06 2020-11-11 Pierre Fabre Medicament Adc pour un traitement concomitant ou postérieur au docétaxel
EP3909612A1 (en) 2020-05-12 2021-11-17 Life Science Inkubator Betriebs GmbH & Co. KG Composition of nanoparticles
US12036286B2 (en) 2021-03-18 2024-07-16 Seagen Inc. Selective drug release from internalized conjugates of biologically active compounds
WO2023240223A2 (en) * 2022-06-10 2023-12-14 Acelyrin, Inc. Anti-igf-1r antibody compositions
EP4353220A1 (en) 2022-10-12 2024-04-17 Pierre Fabre Medicament Use of a liquid aqueous composition for solubilization and stabilization of an antibody-drug conjugate
WO2024180233A1 (en) 2023-03-02 2024-09-06 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts A therapeutic hpv vaccine based on validated target epitopes
WO2024206858A1 (en) 2023-03-30 2024-10-03 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化b−b10
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5767237A (en) 1993-10-01 1998-06-16 Teikoku Hormone Mfg. Co., Ltd. Peptide derivatives
US7241444B2 (en) 2002-01-18 2007-07-10 Pierre Fabre Medicament Anti-IGF-IR antibodies and uses thereof
EP2286844A3 (en) * 2004-06-01 2012-08-22 Genentech, Inc. Antibody-drug conjugates and methods
NZ553500A (en) 2004-09-23 2009-11-27 Genentech Inc Genentech Inc Cysteine engineered antibodies and conjugates withCysteine engineered antibodies and conjugates with a free cysteine amino acid in the heavy chain a free cysteine amino acid in the heavy chain
BRPI0617546A2 (pt) 2005-09-26 2011-07-26 Medarex Inc conjugado de fÁrmaco-anticorpo, formulaÇço farmacÊutica, mÉtodo para matar uma cÉlula de tumor, mÉtodo para retardar ou interromper o crescimento de um tumor em um sujeito mamÍfero e composto
TW200833711A (en) 2006-12-22 2008-08-16 Genentech Inc Antibodies to insulin-like growth factor receptor
AR065803A1 (es) 2007-03-23 2009-07-01 Smithkline Beecham Corp Uso de un polipeptido de il- 18 humana y un anticuerpo anti- cd para preparar unmedicamento
WO2008141044A2 (en) 2007-05-08 2008-11-20 Genentech, Inc. Cysteine engineered anti-muc16 antibodies and antibody drug conjugates
US8937161B2 (en) 2007-10-19 2015-01-20 Genentech, Inc. Cysteine engineered anti-TENB2 antibodies and antibody drug conjugates
WO2009126934A2 (en) 2008-04-11 2009-10-15 Seattle Genetics, Inc. Detection and tratment of pancreatic, ovarian and other cancers
AU2010229192A1 (en) 2009-03-06 2011-09-29 Agensys, Inc. Antibody drug conjugates (ADC) that bind to 24P4C12 proteins
US20100316639A1 (en) * 2009-06-16 2010-12-16 Genentech, Inc. Biomarkers for igf-1r inhibitor therapy
AR080793A1 (es) 2010-03-26 2012-05-09 Roche Glycart Ag Anticuerpos biespecificos
JP5972864B2 (ja) 2010-04-15 2016-08-17 メディミューン リミテッド ピロロベンゾジアゼピン及びそれらのコンジュゲート
ES2528956T3 (es) 2010-06-10 2015-02-13 Seattle Genetics, Inc. Nuevos derivados de auristatina y su uso
CN103379912B (zh) 2010-09-29 2016-03-16 西雅图基因公司 正羧烷基耳他汀及其应用
US9272052B2 (en) * 2010-10-22 2016-03-01 Seattle Genetics, Inc. Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the PI3K-AKT mTOR pathway
JP6105477B2 (ja) 2010-11-05 2017-03-29 ライナット ニューロサイエンス コーポレイション 操作されたポリペプチドコンジュゲートおよびトランスグルタミナーゼを用いてそれを作製する方法
ES2543888T3 (es) 2011-03-16 2015-08-25 Seattle Genetics, Inc. N-carboxialquil-auristatinas y su utilización
US9150644B2 (en) * 2011-04-12 2015-10-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II
MX371526B (es) 2011-05-27 2020-01-31 Ambrx Inc Composiciones que contienen, metodos que incluyen, y usos de derivados de dolastatina enlazados a aminoacidos no naturales.
BR112013030372A2 (pt) 2011-05-27 2016-08-30 Ambrx Inc composições contendo, métodos envolvendo, e usos de derivados de dolastatin ligados ao aminoácido não natural
US8815226B2 (en) 2011-06-10 2014-08-26 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
US10800856B2 (en) 2012-06-07 2020-10-13 Ambrx, Inc. Prostate-specific membrane antigen antibody drug conjugates
EP4406612A3 (en) 2012-06-19 2024-10-16 Ambrx, Inc. Anti-cd70 antibody drug conjugates
US20140017265A1 (en) 2012-07-05 2014-01-16 Mersana Therapeutics, Inc. Terminally Modified Polymers and Conjugates Thereof
AU2013302273A1 (en) 2012-08-14 2015-02-19 Angiochem Inc. Conjugates including an antibody moiety, a polypeptide that traverses the blood-brain barrier, and a cytotoxin
WO2014096551A1 (en) 2012-12-21 2014-06-26 Glykos Finland Oy Linker-payload molecule conjugates
FR3005051A1 (fr) 2013-04-25 2014-10-31 Pf Medicament Derives de la dolastatine 10 et d'auristatines
DK3134124T3 (da) * 2014-04-25 2019-05-06 Pf Medicament Igf-1r-antistof-lægemiddel-konjugat og dens anvendelse til behandling af kræft
SI3134125T1 (sl) * 2014-04-25 2020-02-28 Pierre Fabre Medicament Konjugat zdravila s protitelesom in uporaba le-tega za zdravljenje raka
MA39378B2 (fr) * 2014-04-25 2021-02-26 Pf Medicament Anticorps igf-1r et son utilisation comme véhicule d'adressage pour le traitement du cancer
JP6968790B2 (ja) * 2015-10-26 2021-11-17 ピエール、ファーブル、メディカマン Igf−1r発現癌の処置のための組成物

Also Published As

Publication number Publication date
ES2727103T3 (es) 2019-10-14
AU2015250759A1 (en) 2016-11-10
CA2946469C (en) 2019-10-29
JP2017513900A (ja) 2017-06-01
MA39909B1 (fr) 2019-05-31
CA2946469A1 (en) 2015-10-29
MA47811A (fr) 2019-06-19
DK3134124T3 (da) 2019-05-06
PL3134124T3 (pl) 2019-09-30
KR20160146817A (ko) 2016-12-21
EP3134124A1 (en) 2017-03-01
AU2015250759B2 (en) 2017-11-30
MX2016013704A (es) 2017-03-31
US20200270352A1 (en) 2020-08-27
RS58742B1 (sr) 2019-06-28
BR112016024619A2 (pt) 2017-10-10
RU2016145444A3 (el) 2018-11-22
EP3498301A1 (en) 2019-06-19
SA516380120B1 (ar) 2019-02-27
IL248455A0 (en) 2016-11-30
EP3134124B1 (en) 2019-02-20
WO2015162291A1 (en) 2015-10-29
CN106456800B (zh) 2018-05-01
MA39909A (fr) 2017-03-01
US10633448B2 (en) 2020-04-28
HRP20190888T1 (hr) 2019-07-12
SI3134124T1 (sl) 2019-06-28
HUE044862T2 (hu) 2019-11-28
RU2016145444A (ru) 2018-05-28
IL248455B (en) 2020-01-30
US20170043031A1 (en) 2017-02-16
PT3134124T (pt) 2019-06-03
RU2692563C2 (ru) 2019-06-25
CN106456800A (zh) 2017-02-22
MY186711A (en) 2021-08-12
HRP20190888T8 (hr) 2019-10-04
TN2016000472A1 (en) 2018-04-04
KR101795984B1 (ko) 2017-11-10
LT3134124T (lt) 2019-05-27
JP6258523B2 (ja) 2018-01-10
US11661457B2 (en) 2023-05-30
ES2727103T8 (es) 2020-03-02
UA120364C2 (uk) 2019-11-25

Similar Documents

Publication Publication Date Title
CY1122472T1 (el) Συζευγμα-αντισωματος-φαρμακου και η χρηση αυτου για την αγωγη του καρκινου
CY1121783T1 (el) Συζευγμα αντισωματος-igf-1r-φαρμακου και η χρηση αυτου για την αγωγη του καρκινου
CY1121949T1 (el) Φαρμακοτεχνικες μορφες συζευγματος anti-egfr αντισωματος-φαρμακου
CY1125440T1 (el) Αντι-τιμ-3 αντισωματα και συνθεσεις
CY1124131T1 (el) Συζευγματα αντι-ρτκ7 αντισωματος-φαρμακου
CY1124834T1 (el) Αναστολεις της αλληλεπιδρασης της μηνινης-mll
CY1123858T1 (el) Συζευγματα αντισωματος enanti-cmet δραστικης ουσιας και μεθοδοι για τη χρηση αυτων
CY1121542T1 (el) Μορια αντισωματων σε pd-1 και χρηση αυτων
CY1122510T1 (el) Μορια αντισωματος σε lag-3 και χρησεις αυτων
CO2018005433A2 (es) Conjugados de fármaco de anticuerpo her2 específicos de sitio
MX2021007620A (es) Inmunoconjugados de anticuerpos receptor huerfano similar al receptor tirosina cinasa 1 (ror1).
CY1121849T1 (el) Μεθοδοι και συνθεσεις για τη θεραπεια του καρκινου
CY1121907T1 (el) Συζευγματα antidll3-antiσωmatoς-pbd και χρησεις αυτων
PH12018500693A1 (en) Pyrrolobenzodiazepine antibody drug conjugates and methods of use
CU20170169A7 (es) Anticuerpos de factor xi
MX2021010550A (es) Conjugados de anticuerpo-farmaco hidrofilicos.
BR112016024525A2 (pt) novos anticorpos anti-rnf43 e métodos de uso
GT201700102A (es) Conjugados de anticuerpo-fármaco
EA201900562A1 (ru) Бис-октагидрофенантрена карбоксамиды и их белковые конъюгаты
CY1125150T1 (el) Ενωσεις φαινυλο-2-υδροξυ-ακετυλαμινο-2-μεθυλο-φαινυλιου
BR112018075651A2 (pt) anticorpos anti-cd98 e conjugados anticorpo fármaco
MX2020006010A (es) Conjugados de anticuerpo anti-cd22-maitansina, combinaciones y metodos de uso de los mismos.
DK3870234T3 (da) Antistoflægemiddelkonjugater omfattende ecteinascidinderivater
EA201890457A1 (ru) Комбинации антитела против ox40 и модулятора tlr4 и их применение
CY1124183T1 (el) Συζευγματα αντισωματος εναντι-sez6 φαρμακου και μεθοδοi χρησης